This phase 2 randomized clinical trial evaluates the optimal dose, dosing interval, and safety of zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), to treat patients with atherosclerotic cardiovascular disease and elevated lipoprotein(a) concentration.
